Sunday share tips: Gym Group, Concepta

But interim results this coming week are likely to confirm the company is muscling its way towards a 66% annual gain in adjusted pre-tax profits. For the first six months of the year, the offer of £16-per-month membership helped attract 23% more new members than in the first half last year. A monthly fee that is around five times cheaper than its rivals should help Gym group if there is a sustained Brexit slowdown. Although prices are cheap, the company cuts costs by keeping the joining process online and investing in other technology, and cash generation is strong, with net debt more than halved so far this year. It looks in good shape.

Concepta is a small company but worth buying, said Midas in the Mail on Sunday. It has developed a diagnostic kit that tests for women's fertility and is also a pregnancy test. Around a third of women with unexplained infertility issues have low levels of the luteinising hormone associated with ovulation, but for which Concepta's MyLotus device is the first commercially available kit. The reusable meters, which will sell for £250-350 when they go on sale, use a urine test like normal pregnancy tests but the highly accurate readings will tell users when they are most likely to become pregnant.

MyLotus has been approved by regulators in China, and are due to begin selling there this year, while UK and European approval is expected by 2018. Helping the China launch, when women log on to hospital wifi systems, they will be met with an advert for MyLotus. Manufacturing has already been arranged in China and a local distributor has been appointed, initially focusing on 20 hospitals before being rolled out further. Other products in the Concepta pipeline include those to diagnose stress, which can affect fertility and might also be applicable outside the fertility market.

Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only and not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.